FDA Authorized Rapid COVID-19 Antibody Testing
Maintain social distancing and get tested at home by Mobile IV Medics. Our nurses come to you for testing with full appropriate PPE for $219.
Our Rapid COVID-19 Test is designed to detect proteins the human body Our FDA emergency use authorized (EUA) Rapid COVID-19 Test is designed to detect proteins the human body makes in response to exposure to SARS-CoV-2 or having COVID-19. These proteins, called antibodies, begin to appear in the blood several days to weeks after a person becomes infected.
If you have questions, please visit our FAQ Page here!
How We Do Testing: 3 Easy Steps to Your Result
Time needed: 25 minutes.
- Schedule Online For A Time & Place
A nurse will come to your house to administer the test.
- We collect a sample collection
We’ll do a fingerstick to collect a sample of your blood for testing.
- Get your results
We will present your results typically 10-15 minutes after the test.
Information about COVID-19 can be found on the CDC Coronavirus (COVID-19) website.
Information about COVID-19 antibody tests can be found on the CDC COVID-19 Antibody Test website.
Schedule Your Appointment
The U.S. Food and Drug Administration (FDA) has authorized this test for emergency use (EUA). This authorization and the issued Updated Policy Guidance on March 16, 2020 enables the availability and distribution of the COVID-19 IgG/IgM Rapid Diagnostic Test. However, the U.S. Food and Drug Administration (FDA) has not cleared or approved the COVID-19 IgG/IgM Rapid Diagnostic Test. The U.S. Secretary of Health and Human Services (HHS) has declared that circumstances exist to allow the emergency use of diagnostic tests for COVID-19, such as the COVID-19 IgG/IgM Rapid Diagnostic Test. The FDA has allowed the distribution and use of the COVID-19 IgG/IgM Rapid Diagnostic Test to test for antibodies to SARS-CoV-2 in your specimens only for the duration of the emergency, unless it is terminated or revoked by FDA sooner.
- Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic (oral or nasal swab) should be considered to rule out infection in these individuals
- Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status
- Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E